Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,
Tag: cytokine release syndrome
Cytokine Release Syndrome 2.0: Managing Immune-Effector Toxicity as Cell Therapy Moves Earlier, Broader, and Beyond CAR T
Cytokine Release Syndrome 2.0: Managing Immune-Effector Toxicity as Cell Therapy Moves Earlier, Broader, and Beyond CAR T Review Abstract Purpose: This article reviews cytokine release syndrome (CRS) and related immune-effector toxicities in the expanding era of cellular therapy, with emphasis on practical recognition, risk stratification,
Thrombosis and Cancer Immunotherapy: The Next Frontier of Thromboinflammation
Thrombosis and Cancer Immunotherapy The Next Frontier of Thromboinflammation Review Abstract Cancer immunotherapy has fundamentally transformed the treatment landscape across multiple malignancies, offering durable responses and prolonged survival in patients with previously limited therapeutic options. Immune checkpoint inhibitors, chimeric antigen receptor T cell therapies, bispecific antibodies,
